Integral BioSystems seeks seed funding for two ophthalmic platforms

Integral BioSystems said it is seeking seed round financing for two eye-care products, the NanoM-Wafer Lubricating Bandage and OcuHeal-UV400+, through its subsidiary Symphony Therapeutics. The Bedford, Massachusetts, company is positioning both as device-based treatments for dry eye and UV-related ocular protection, with initial commercialization planned for Europe.

Why it matters: - Integral BioSystems is trying to move two proprietary ophthalmic platforms from development into commercialization. - The two products target large unmet needs in dry eye disease and UV-related eye protection. - Both programs are being funded through a seed round tied to Symphony Therapeutics, the company’s wholly owned subsidiary.

What happened: - Integral BioSystems said it is seeking seed round financing for the NanoM-Wafer Lubricating Bandage and OcuHeal-UV400+. - The funding effort runs through Symphony Therapeutics, LLC, based with Integral BioSystems in Bedford, Massachusetts. - The company is asking for micro-funding and pharma collaborations to support development.

The details: - The NanoM-Wafer Lubricating Bandage is designed to treat dry eye symptoms linked to meibomian gland dysfunction and Sjögren’s syndrome. - The product is intended to be self-administered and placed under the lower eyelid with a gloved hand. - The wafer is designed to hydrate on the ocular surface and convert into a transparent hydrogel. - The hydrogel is designed to last 11 to 13 hours before slowly dissolving. - The product does not contain a drug. - The formulation uses ophthalmologically compatible polymers, lipids and a hydration-enhancing excipient. - Integral BioSystems says the design is meant to stimulate tear mucin production and help restore tear film components. - The company is developing the NanoM-Wafer Lubricating Bandage as a medical device for launch first in Europe, then other countries. - The platform has also been described as a next-generation version of Lacrisert, with a more biomimetic design and better tissue interaction. - Prototypes have been tested in rabbit eye models for safety and tolerability. - Integral BioSystems says the NanoM-Wafer platform could also support future products for presbyopia, cystinosis and glaucoma. - OcuHeal-UV400+ is based on the company’s lipid nanoparticle platform technology. - The product incorporates an UV-blocking antioxidant into nanostructured, liquid-crystalline lipid nanoparticles. - The formulation is designed to block UV-A and UV-B and add blue-light blocking from the encapsulated nanoparticles. - The company says the compound is biocompatible with corneal epithelial cells, quenches free radicals and supports anti-fibrotic healing in injured corneal tissue. - OcuHeal-UV400+ eyedrops showed more than 6 hours of residence time on the ocular surface in New Zealand White rabbit eyes. - The company has completed 12-month cGLP stability studies and is continuing process development. - Integral BioSystems is also developing related lipid nanoparticle products for allergic rhinitis and skin regeneration. - OcuHeal-UV400+ is being developed as a protective medical device for initial introduction in Europe, followed by other countries.

Between the lines: - The company is leaning on a device-based regulatory path rather than a traditional drug model for both programs. - That approach could shape how quickly the products reach market and how they are positioned clinically. - The emphasis on patents, platform reuse and multiple future indications suggests Integral BioSystems is building a broader product family, not just two standalone products. - The company’s reliance on prior CRO revenue and boot-strapping indicates development has so far been largely internally financed.

What's next: - Integral BioSystems will look to raise seed capital through Symphony Therapeutics to finish development work. - The company plans to pursue additional patent filings. - Commercial rollout is expected to start in Europe for both platforms before expansion to other markets. - Interested partners can contact the business development team at info@integralbiosystems.com.

The bottom line: - Integral BioSystems is trying to turn two patented ophthalmic platforms into fundable, device-based products with broad clinical potential and global ambitions.